| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D261-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 |
| filingDate |
2015-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f8bd96ec67990b3f71c5e48f74f78ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a4deed1482dc56ea31cc1b726054a04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ffa005c55ad6f52a6645a28fd83da48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08f89b8d3d32fc597a930e6a5a455c9f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dd5586c72ee86d31869c2b13bded383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78c9438e5f0afd5ffeb76e57e22ee2b9 |
| publicationDate |
2020-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-I693215-B |
| titleOfInvention |
Isoxazole hydroxamic acid compounds as LPXC inhibitors |
| abstract |
This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria. |
| priorityDate |
2014-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |